X

Trial Profile

Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti MUC1 CAR T cell/PD-1 knockout engineered T cell therapy Guangzhou Anjie Biomedical Technology (Primary) ; Anti-MUC1 CAR-T cell therapy; PD-1 knockout T-cells
Indications Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

06 Jun 2023 Results (n=9) reporting efficacy and safety data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
03 Jul 2021 Results(n=8) cutoff date (February 11, 2021) assessing safety and efficacy of PD-1 knockout engineered anti-MUC1 CART cells in the treatment of patients with advanced oesophageal cancer presented at the 23rd World Congress on Gastrointestinal Cancer
25 Oct 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com